Phase I/pharmacology study of intraperitoneal (IP) 3-5 day topotecan alone and with cisplatin:on day 1: potential for consolidation in ovarian cancer
作者： E. Andreopoulou , T. Chen , L. Liebes , J. Lu , S. Moore
DOI: 10.1200/JCO.2005.23.16_SUPPL.5045
关键词:
摘要: 5045 Background: Consolidation following 1st-line treatment is a strategy being explored to improve results in advanced ovarian cancer. Topotecan has schedule dependent toxicity alone and combinati...
sci-hub.st 参考文章(0)